286 related articles for article (PubMed ID: 33738447)
1. The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Majd NK; Yap TA; Koul D; Balasubramaniyan V; Li X; Khan S; Gandy KS; Yung WKA; de Groot JF
Neurooncol Adv; 2021; 3(1):vdab015. PubMed ID: 33738447
[TBL] [Abstract][Full Text] [Related]
2. The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas.
Majd N; Yap TA; Yung WKA; de Groot J
J Immunother Precis Oncol; 2020 Nov; 3(4):157-164. PubMed ID: 35665372
[TBL] [Abstract][Full Text] [Related]
3. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract][Full Text] [Related]
4. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Ferri A; Stagni V; Barilà D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
Gupta SK; Smith EJ; Mladek AC; Tian S; Decker PA; Kizilbash SH; Kitange GJ; Sarkaria JN
Front Oncol; 2018; 8():670. PubMed ID: 30723695
[TBL] [Abstract][Full Text] [Related]
6. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
7. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
Talele S; Zhang W; Burgenske DM; Kim M; Mohammad AS; Dragojevic S; Gupta SK; Bindra RS; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2021 Dec; 379(3):343-357. PubMed ID: 34556535
[TBL] [Abstract][Full Text] [Related]
8. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
9. Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development.
Bisht P; Kumar VU; Pandey R; Velayutham R; Kumar N
Front Pharmacol; 2022; 13():939570. PubMed ID: 35873570
[TBL] [Abstract][Full Text] [Related]
10. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
Front Oncol; 2021; 11():648687. PubMed ID: 34026622
[TBL] [Abstract][Full Text] [Related]
12. Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.
Morgan MA; Canman CE
Cancer Res; 2018 Dec; 78(24):6713-6716. PubMed ID: 30498082
[TBL] [Abstract][Full Text] [Related]
13. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress.
Kaur E; Ketkar M; Dutt S
Med Oncol; 2022 Feb; 39(5):50. PubMed ID: 35150325
[TBL] [Abstract][Full Text] [Related]
15. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
16. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
17. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
19. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.
Chalmers AJ
Anticancer Agents Med Chem; 2010 Sep; 10(7):520-33. PubMed ID: 20879987
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
